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Abstract
We investigated the prognostic ability of preoperative monocyte–lymphocyte ratio for oncologic outcomes in non-metastatic clear
cell renal cell carcinoma of 7cm on preoperative computed tomography (CT).
We retrospectively reviewed 1637 patients who underwent radical or partial nephrectomy for solid renal masses 7cm (2005–
2014). We included 1137 patients after exclusion of benign pathology, non-clear cell, morbidity affecting inﬂammatory markers,
metastasis, regional lymphadenopathy, positive margin, and follow up <12 months. According to cutoff values of 0.21, we had high
≥0.21 and low <0.21 preoperative monocyte–lymphocyte ratio groups. Mann–Whitney U and chi-squared tests were used for
continuous and Dichotomous variables. Univariate and multivariate Cox regression analysis were used to predict factors affecting
recurrence and survival. Kaplan–Meier curve was used for survival analysis.
At a median age of 56 years with a median follow up of 65 months, 51 patients had a recurrence (4.5%). There were no statistical
differences between the high and low monocyte–lymphocyte ratio groups as regard the pathological characters (P> .005).
Monocyte–lymphocyte ratio was a predictor for recurrence-free and cancer-speciﬁc survivals (hazard risk [HR] 2.17, P= .012 and HR
4.06, P= .004, respectively). A higher monocyte–lymphocyte ratio was signiﬁcantly associated with worse, both 10-year recurrence-
free (90.2% vs 94.9%) and cancer-speciﬁc survival (89.5% vs 98.8%) (Log-rank, P= .002 and P< .001, respectively).
The preoperative monocyte–lymphocyte ratio is an independent prognostic marker for recurrence-free and cancer-speciﬁc
survivals after curative surgery for non-metastatic clear cell renal cell carcinoma of 7cm on preoperative CT.
Abbreviations: CCI=Charlson comorbidity indexes, ccRCC= clear-cell renal cell carcinoma, CSS= cancer-speciﬁc survival, CT
= computed tomography, HR = hazard risk, IQR = interquartile range, LMR = lymphocyte–monocyte ratio, MLR = monocyte–
lymphocyte ratio, RCC = renal cell carcinoma, RFS = recurrence-free survival, TAMs = tumor-associated macrophages, TME =
tumor microenvironment.
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In the last few decades, the incidence of renal cell carcinoma
(RCC) is slightly increasing with clear cell RCC (ccRCC) is the
most common variant (60–70%).[1] Due to the widespreadEditor: Vito Mancini.
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1practice of abdominal imaging, most of newly diagnosed cases
are organ conﬁned (up to 80%) with the surgical resection is
considered as the gold standard treatment. However, recurrence
may take place (up to 20%) with a pronounced deterioration in
cancer speciﬁc survival (CSS).[2] Several prognostic models have
been exploited to adopt the best management and follow up
options, as once metastasis takes place, the 5-year survival will be
below 20%.[3]
Nowadays, most prognostic tools depend on postoperative
pathologic ﬁndings. However, there are diverse outcomes even
for cases who share similar clinico-pathological characters, so the
evolution of tumor associated immunohistochemical and blood-
based biomarkers can help more accurate prognosis.[4,5]
RCC is an immunogenic cancer that showed response to
immunologic therapy.[6,7] Immunologic dysfunctionhas frequently
accused of oncogenesis and progression of RCC as a quite
proportion of patients with ccRCC harbor mutations of Janus
Kinase (JAK3) gene which mediates cytokine signaling and T-cell
function.[8,9] Besides, the cancer associated imbalance in antigen-
presenting cells (i.e., dendritic cells) which normally play an
antitumor effect by capturing tumor-speciﬁc antigen to regional
lymphaticswhere tumor-speciﬁcT-cells become ready for action.[7]
In the tumor microenvironment (TME), both lymphocytes and
monocytes are representing host immunity and tumor aggres-
siveness respectively for many cancers including RCC.[10,11]
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independent association with various tumors.[12,13] Most of the
articles about the preoperative inﬂammatory biomarkers studied
the prognostic impact on metastatic RCC.[14,15] Despite the all
mentioned above, there is a lack of sufﬁcient data in the literature
as regarding the monocyte–lymphocyte ratio (MLR) as a
pretreatment prognostic model that help the stratiﬁcation of
non-metastatic ccRCC. Thus, the aim of our study is to measure
prognostic value of preoperative MLR in non-metastatic ccRCC
7cm on preoperative computed tomography (CT).2. Methods
2.1. Patient
Based on our Institutional Review Board guidelines of the Yonsei
University Health System (project number: 4–2018–0215) that
conform to the provisions of the Declaration of Helsinki (as
revised in Fortaleza, Brazil, October 2013), we retrospectively
reviewed the renal tumor database of 1637 patients who
underwent radical or partial nephrectomy for solid renal masses
7cm on preoperative CT between 2005 and 2014. We ﬁnally
included 1137 patients with clinically localized unilateral ccRCC
(pT1–3N0M0) after exclusion of cases with benign pathology,
non-clear cell type, preoperative morbidity affecting inﬂamma-
tory markers (i.e., chronic liver disease, immunosuppression,
hematologic and non-hematologic malignancies, autoimmune
diseases, and chronic inﬂammatory diseases), metastasis, lymph
nodes involvement in preoperative CT scan, positive margin,
short postoperative follow up <12 month, and those with
missing data of the preoperative laboratory parameters within 1
month prior to surgery as shown in the ﬂow chart (Fig. 1).
All patients were evaluated for metastasis and lymph node
status by CT, chest radiographs, and bone scans preoperatively.
No patient received adjuvant treatment. Blood monocyte and
lymphocyte counts were obtained within a month prior surgery.
Pathological outcomes were based on previous pathological
reports without reanalysis because most of the pathological slides
had been interpreted by a single genitourinary pathologist at ourFigure 1. A ﬂow chart showing the algorithm of database selection after
application of inclusion and exclusion criteria. MLR=monocyte–lymphocyte
ratio.
2institute. Tumors were classiﬁed based on TNM system of the
2010 American Joint Committee on Cancer (AJCC)[16] and
Fuhrman grading.[17]2.2. Follow-up evaluations
Follow-up examinations consisting of physical examination, serum
chemistry evaluation, chest radiography, and abdominal-pelvic CT
were performed semi-annually for the ﬁrst 3 years and annually
thereafter. Recurrence was deﬁned as the ﬁrst detection of either a
local or distant recurrence. To assess CSS, the survival status and
the cause of death were investigated using the national cancer
registry database and institutional electronic medical records.2.3. Statistical analysis
MLRwas evaluated as a dichotomized variable by dividing cases
into 2 groups (highMLR and lowMLR). Using the Shapiro–Wilk
test, we rejected the hypothesis that continuously coded clinical
variables (i.e., age, body mass index, follow-up duration) are
normally distributed (P< .001). Thus, they were presented as the
median and interquartile range (IQR).Mann–WhitneyU and chi-
squared tests were used to compareMLR groups with continuous
and dichotomized variables, respectively.
The endpoints of the study were the recurrence-free survival
(RFS) and CSS. For survival analysis, Kaplan–Meier with the log-
rank test was used. The relative risk was assessed by 95%
conﬁdence intervals (CI) of hazard risk (HR). The variables that
achieved statistical signiﬁcance in the univariate analysis were
subsequently enrolled in the multivariate analysis with Cox
proportional hazards regression model with a backward variable
selection approach. All tests were 2-sided, with statistical
signiﬁcance set at (P< .05). Statistical analysis was performed
using SPSS version 18 (SPSS Inc., Chicago, IL).
3. Results
3.1. The optimal cutoff for MLR
As there were no clinically known cutoff values for MLR, the
optimal cutoff value was determined as (0.21), which was
calculated by the receiver operating curve (ROC) analysis. The
areas under the curve (AUCs) based on end-points of RFS and
CSS were 0.585 (sensitivity=60.8%, speciﬁcity=59.3%) and
0.669 (sensitivity=73.9%, speciﬁcity=61%), respectively, as
shown in (Fig. 2). MLRwas evaluated as a dichotomized variable
by dividing cases into 2 groups (MLR <0.21 and MLR ≥0.21).
3.2. Associations of clinico-pathologic features with MLR
levels
A total of 1137 patients met our study inclusion criteria. In the 819
men and 318 women, median age at surgery was 56 years (IQR
46.5–65). Themedian counts ofmonocytes and lymphocytes were
0.38109/L (IQR 0.30–0.48) and 2109/L (IQR 1.6–2.4),
respectively. Median MLR value was 0.19 (IQR 0.15–0.25).
Total of 664 (58.4%)hadMLR<0.21 and473 (41.6%)hadMLR
≥0.21. Clinico-pathologic features for patients with preoperative
MLR<0.21and≥0.21areprovided inTable1.PatientswithMLR
≥0.21weremore likely tobemenwith anolder age andhaveworse
Charlson comorbidity indexes (CCI) score (all, P< .05). There
were no signiﬁcant differences in pathologic and radiologic
featuresbetween the2groups.However, patientswithMLR≥0.21
tended to have a greater nuclear grade (P= .064).
Figure 2. Optimal cutoff levels for MLR were applied at 0.21 using receiver operating curve. (A) Considering recurrence-free survival as a state variable. (B)
Considering cancer-speciﬁc survival as a state variable. AUC=area under the curve, MLR=monocyte–lymphocyte ratio.
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In univariate analyses, MLR ≥0.21 was associated with 2.4-fold
increased risk or recurrence (P= .003) and with 4.4-fold
increased risk of death from the disease (P= .002). The signiﬁcant
factors in univariate analysis were used to determine the inﬂuence
on both RFS and CSS by multivariate analyses with a backward
variable selection. MLR ≥0.21 was an independent predictor of
RFS (HR 2.17, P= .012), among other predictors such as CCI
score (HR 2.58, P= .004), greater clinical tumor size (HR 3.92,
P< .001) and greater pathological T stage (HR 4.78, P< .001),
while other factors like age, Fuhrman grade, and Preoperative
aspects and dimensions used for anatomic classiﬁcation
(PADUA) score were excluded at earlier steps in the backward
variable selection (Table 2). As regard CSS, multivariate analyses
revealed that MLR ≥0.21 was an independent predictor of CSS
(HR 4.06, P= .004). Meanwhile, greater clinical tumor size (HR
2.50, P= .050) and greater pathological T stage (HR 8.62,
P< .001) were considered to be independent indictors for CSS
(Table 3).
The median follow-up after surgery was 65 months (IQR 43–
91), during that time, 51 patients experienced a disease
recurrence at a median 63 months following surgery (IQR
30–105). Moreover, 67 died at a median 43 months after
surgery (IQR 23–72) with 23 represent cancer-speciﬁc death at a
median 38 months after surgery (IQR 22–70). The RFS rates in
patients with MLR <0.21 was 97.2% at 5 years and 94.9% at
10 years, signiﬁcantly higher than the 93.7% at 5 years and
90.2% at 10 years in patients with MLR ≥0.21 (log-rank,
P= .002; Fig. 3A). The 5 years and 10 years for CSS rates were
signiﬁcantly higher in MLR <0.21 than in MLR ≥0.21 (96.9%
and 90.8%) versus (93.7% and 79.7%) (Logrank, P= .001;
Fig. 3B).34. Discussion
The reliability of the blood-based biomarkers for prediction of
tumor progression is still under thorough investigations.[18,19]
We showed that a greater preoperative MLR was independently
correlated with poor RFS and CSS for patients with non-
metastatic ccRCC 7cm in the preoperative CT.
Tumor progression and its poor outcome can be greatly
inﬂuenced by inﬂammation, considering the report that main
immune cells present in the TME of ccRCC are macrophages.[20]
Blood monocytes differentiate into tumor-associated macro-
phages (TAMs) that concentrate by chemokines in TME.[21]
TAMs give rise to M2 macrophages which have a pro-tumor
effect by stimulating angiogenesis, tumor cell growth, metastatic
niche formation, and counteracting the T-lymphocytes mediated
antitumor mechanism.[22,23] Based on in this, antitumor
immunotherapies have been developed since early 1990s to
antagonize the trophic effect of TAMs in TME.[24]
Higher bloodmonocytes count reﬂects macrophages load in the
TME, which has proven to have a predictive role for poor clinical
outcome in ccRCC.[25] In the contrary, high lymphocytes density in
TME represents an immunologic anti-tumor reaction, and
therefore, peripheral leucopenia is an indicator of aworse outcome
of various tumors including ccRCC.[11] Moreover in RCC, there
are associated poor quality of CD8+ T as well as defects in JAK3/
STAT5/6 intracellular cytokine mediated signaling pathway leads
to arrest of T-lymphocytes towards their terminal differentia-
tion.[8,9] In RCC patients, dendritic cells were scanty in the
peripheral blood while being more concentrated in RCC tissue as
compared with healthy kidney tissue.[7]
The MLR was previously described in the literature as an
independent prognostic factor in non-metastatic ccRCC. An
Austrian study that was considered including the largest sample
Table 1
Patient and tumor characteristics according to preoperative monocyte–lymphocyte ratio.
Total (n=1137) MLR <0.21 (n=664) MLR ≥0.21 (n=473) P
∗
Follow up, mo 65 (43–91) 69.5 (46–94) 60 (41–85) .001
Age, y 56 (46.5–65) 55 (46–63) 57 (47–67) .004
Gender <.001
Male 819 (72.0%) 445 (67.0%) 374 (79.1%)
Female 318 (28.0%) 219 (33.0%) 99 (20.9%)
BMI 24.3 (22.5–26.4) 24.3 (22.6–26.5) 24.22 (22.5–26.2) .482
NLR 1.85 (1.39–2.51) 1.60 (1.22–2.01) 2.30 (1.77–3.29) .000
PNI 54.95 (51.85–58.40) 56.43 (53.35–59.69) 53.05 (49.55–56) .000
CCI .027
2 696 (61.2%) 427 (64.3%) 269 (57.1%)
3–4 297 (26.2%) 165 (24.9% 132 (28.0%)
≥5 141 (12.4%) 71 (10.7%) 70 (14.9%)
Pathological T stage .496
T1 1019 (89.6%) 601 (90.5%) 418 (88.4%)
T2 7 (0.6%) 4 (0.6%) 3 (0.6%)
T3 111 (9.8%) 59 (8.9%) 52 (11.0%)
Fuhrman grade .064
G1–2 698 (61.4%) 423 (63.7%) 275 (58.1%)
G3–4 439 (38.6%) 241 (36.3%) 198 (41.9%)
PADUA score sum .652
6–7 268 (23.6%) 162 (24.4%) 106 (22.4%)
8–9 460 (40.5%) 262 (39.5%) 198 (41.9%)
≥10 409 (36.0%) 240 (36.1%) 169 (35.7%)
PADUA classiﬁcation
Longitudinal location .429
Superior or inferior 485 (42.7%) 290 (43.7%) 195 (41.2%)
Mid-polar 652 (57.3%) 374 (56.3%) 278 (58.8%)
Exophytic rate .455
≥50% 384 (33.8%) 221 (33.3%) 163 (34.5%)
<50% 528 (46.4%) 318 (47.9%) 210 (44.4%)
Endophytic 225 (19.8%) 125 (18.8%) 100 (21.1%)
Rim location .214
Lateral 712 (62.6%) 426 (64.2%) 286 (60.5%)
Medial 425 (37.4%) 238 (35.8%) 187 (39.5%)
Renal sinus .802
Not involved 727 (63.9%) 427 (64.3%) 300 (63.4%)
Involved 410 (36.1%) 237 (35.7%) 173 (36.6%)
Collecting system .390
Not involved 684 (60.2%) 392 (59.0%) 292 (61.7%)
Involved 453 (39.8%) 272 (41.0%) 181 (38.3%)
Radical or partial .428
Radical 476 (41.9%) 271 (40.8%) 205 (43.3%)
Partial 661 (58.1%) 393 (59.2%) 268 (56.7%)
Data are presented as number (%) or median (interquartile range).
BMI=body mass index, CCI=Charlson comorbidity index, MLR=monocyte–lymphocyte ratio, PADUA=preoperative aspects and dimensions used for anatomic classiﬁcation.
∗
P-value from comparison between (MLR <0.21) and (MLR ≥0.21).
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speciﬁc death with Low (LMR <3) when compared with high
(LMR ≥3). However, there was no statistically signiﬁcant
association with RFS.[26] Further Chinese study included 430
cases showed the correlation of preoperative LMRwith both RFS
and overall survival.[27] Lucca et al[28] studied 430 patients and
concluded that MLR with cutoff value of 0.4 have the most
relevant prognostic ability when compared with the neutrophil to
lymphocyte ratio, the platelet to lymphocyte ratio, and the
prognostic nutritional index. Our study showed that higher
preoperative MLR has a higher tendency to have a greater
Fuhrman nuclear grade which is consistent with the systematic
review and meta-analysis by Gu et al.[29]
The strength points in our study is that the MLR is a cost-
effective, readily available biomarker which can be added to
already valid or upcoming stratiﬁcation scores predicting4prognosis and assisting decision-making. We included the largest
sample size of patients among studies that handled the prognostic
role of hematologic scoring systems in RCC especially the
MLR.[30,31] All cases derived from a single center and were
subjected to the same standardized protocol of blood sampling,
laboratory techniques, surgical procedure, pathological evalua-
tion, and follow-up strategy.
We only included clinical tumor size 7cm, which may be
considered as a drawback of the study. However, this established
the homogeneity of our cohort as tumor size may inﬂuence white
blood cells count and survival. Another drawback is the
retrospective nature of the study design and selection bias. One
of the common limitations of such studies is that the median value
of inﬂammatory markers and may show racial differences of the
target population[32] as compared with other series come from
different parts in the world with the subsequent differences in the
Table 2
Univariate and multivariate analyses for factors predicting
recurrence-free survival.
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age, y 1.04 (1.02–1.06) .001
Gender
Male Ref.
Female 0.63 (0.32–1.26) .192
BMI 1.02 (0.94–1.12) .590
CCI
2 Ref. Ref.
3–4 2.81 (1.55–5.12) <.001 2.58 (1.35–4.93) .004
>5 1.97 (0.87–4.47) .106 1.54 (0.63–3.76) .345
Clinical tumor size
<4 Ref. Ref.
4–7 4.72 (2.58–8.62) <.001 3.92 (2.06–7.47) <.001
Pathological T stage
T1 Ref. Ref.
T2 4.20 (0.57–30.84) .158 3.32 (0.37–29.78) .283
T3 7.23 (4.10–12.74) <.001 4.78 (2.51–9.11) <.001
Fuhrman grade
G1–2 Ref.
G3–4 2.23 (1.28–3.89) .005
PADUA score sum
6–7 Ref.
8–9 1.31 (0.50–3.40) .586
≥10 3.12 (1.30–7.41) .011
MLR groups
<0.21 Ref. Ref.
≥0.21 2.35 (1.34–4.13) .003 2.17 (1.19–3.97) .012
CCI=Charlson comorbidity index, CI=conﬁdence interval, HR=hazard ratio, MLR=monocyte–
lymphocyte ratio, PADUA=preoperative aspects and dimensions used for anatomic classiﬁcation.
Table 3
Univariate andmultivariate analyses for factors predicting cancer-
speciﬁc survival.
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age, y 1.05 (1.01–1.09) .013
Gender
Male Ref.
Female 0.39 (0.12–1.32) .131
BMI 0.90 (0.78–1.05) .172
CCI
2 Ref.
3–4 0.24 (0.08–0.70) .008
>5 0.69 (0.24–1.93) .473
Clinical tumor size
<4 Ref. Ref.
4–7 0.21 (0.12–0.39) <.001 2.50 (1.00–6.24) .050
Pathological T stage
T1 Ref.
T2 0.00 (0.00–2.94) .979 0.00 (0.00–0.00) .999
T3 11.37 (5.01–25.79) <.001 8.62 (3.56–20.87) <.001
Fuhrman grade
G1–2 Ref.
G3–4 3.24 (1.37–7.65) .007
PADUA score sum
6–7 Ref.
8–9 2.15 (0.46–10.12) .333
≥10 3.51 (0.79–15.60) .099
MLR groups
<0.21 Ref. Ref.
≥0.21 4.44 (1.75–11.27) .002 4.06 (1.55–10.59) .004
CCI=Charlson comorbidity index, CI= conﬁdence interval, HR=hazard ratio, MLR=monocyte–
lymphocyte ratio, PADUA=preoperative aspects and dimensions used for anatomic classiﬁcation.
Figure 3. Kaplan–Meier curves according to preoperative MLR. (A) Recurrence-free survival. (B) Cancer-speciﬁc survival. MLR=monocyte–lymphocyte ratio.
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[12] Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to
Elghiaty et al. Medicine (2018) 97:48 Medicinecutoff values which can be enforced by using different statistical
tools.[28] Further limitation is the need to add other biomarkers to
enhance predictability, and there should be further studies on the
inﬂammatory cells in theTMEof the tumor itselfwith following up
the postoperative circulating levels.[20,33] Besides, there may be
other conditions inﬂuencing this correlation.[34]
Recent reviews have shown that various cancers have an
inﬂuence on MLR such as colorectal carcinoma, soft tissue
sarcoma, Hodgkin lymphoma, and other non-hematological
malignancies.[12,13,29] Peripheral lymphopenia also predicts poor
prognosis in other malignancies such as esophageal carcino-
ma.[35] That is the reason why we have excluded many cases with
preexisting preoperative conditions (i.e., chronic inﬂammatory
conditions, malignancies, immunosuppression, preoperative
lymph node involvement, metastasis, or autoimmune disease)
that may alter the circulating inﬂammatory cells count in
peripheral blood and we included one pathologic type of RCC to
avoid heterogeneity of study cohort. In conclusion,MLR can help
preoperative evaluation and predicting outcome for patients with
non-metastatic clear cell renal cell carcinoma of 7cm on
preoperative CT after curative surgery.
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